All In Biotech

Drug Trial Radar · NCT05851092

Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors

A Single Arm, Open, Multicenter Phase I Clinical Study on the Safety, Tolerance, and Pharmacokinetics of HRS-2189 Single Drug in Patients With Advanced Malignant Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jul 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

May 26, 2023

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
May 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and anti-tumor efficacy characteristics of HRS-2189 single drug in patients with advanced malignant solid tumors. This study was divided into three stages: dose escalation, dose expansion, and efficacy expansion.

Conditions

  • Advanced Malignant Tumor

Interventions

  • HRS-2189 TabletsDrug

    HRS-2189 Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AEs+SAEsTime frame: from the first drug administration to within 30 days for the last treatment dose
  2. Dose limited toxicity (DLT) of HRS-2189Time frame: up to 35 days
  3. Maximum tolerated dose(MTD)of HRS-2189Time frame: up to 35 days
  4. Recommended Phase II Dose (RP2D) of HRS-2189Time frame: up to 35 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.